Madrigal Secures $4.4B Ribo siRNA Deal with $60M Upfront for MASH Expansion
Madrigal has struck a $4.4 billion siRNA licensing agreement with Ribo, securing a $60 million upfront payment and six preclinical MASH candidates. The deal deepens its MASH pipeline and prepares for planned FDA submissions of siRNA therapies in 2026.
1. siRNA Licensing Agreement
Madrigal Pharmaceuticals and Ribo entered a licensing pact valued at $4.4 billion in potential milestones, with Madrigal receiving a $60 million upfront payment. The agreement grants Madrigal rights to novel siRNA assets targeting metabolic dysfunction-associated steatohepatitis.
2. MASH Pipeline Expansion
Through the deal, six preclinical siRNA candidates join Madrigal's existing MASH portfolio, broadening its therapeutic approach beyond small-molecule inhibitors. This expansion enhances the company’s ability to address multiple disease pathways in MASH.
3. Regulatory and Financial Outlook
The collaboration sets the stage for FDA submissions of the newly licensed siRNA therapies in 2026, aligning with Madrigal’s development timeline. The upfront cash infusion bolsters its balance sheet, supporting further research and potential long-term revenue growth.